Nombre del producto:Di-tert-butyl 1-ethynylhydrazine-1,2-dicarboxylate

IUPAC Name:N'-[(tert-butoxy)carbonyl]-N-ethynyl(tert-butoxy)carbohydrazide

CAS:1353745-17-1
Fórmula molecular:C12H20N2O4
Pureza:95%
Número de catálogo:CM1075334
Peso molecular:256.3

Unidad de embalaje Stock disponible Precio($) Cantidad

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :1353745-17-1
Fórmula molecular:C12H20N2O4
Punto de fusión:-
Código de sonrisas:O=C(N(C#C)NC(OC(C)(C)C)=O)OC(C)(C)C
Densidad:
Número de catálogo:CM1075334
Peso molecular:256.3
Punto de ebullición:
Nº Mdl:
Almacenamiento:

Category Infos

Aliphatic Chain Compounds
Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

Column Infos

INX-315
Incyclix Bio announces FDA clearance of investigational new drug application for INX-315 in patients with advanced or metastatic cancer. INX-315 is a novel, potent and selective inhibitor of Cyclin-dependent kinase 2 (CDK2) with compelling pre-clinical efficacy and safety data.
CDK2 is thought to play an important role in driving proliferation of certain cancers, including those harboring CCNE1 amplification and breast cancers that have acquired resistance to CDK4/6 inhibitors (CDK4/6i).